These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 24037487)

  • 1. Receptor change-clinicopathologic analysis of matched pairs of primary and cerebral metastatic breast cancer.
    Bachmann C; Grischke EM; Staebler A; Schittenhelm J; Wallwiener D
    J Cancer Res Clin Oncol; 2013 Nov; 139(11):1909-16. PubMed ID: 24037487
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CNS metastases of breast cancer show discordant immunohistochemical phenotype compared to primary.
    Bachmann C; Grischke EM; Fehm T; Staebler A; Schittenhelm J; Wallwiener D
    J Cancer Res Clin Oncol; 2013 Apr; 139(4):551-6. PubMed ID: 23224376
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk factors and survival outcome in cerebral metastatic breast cancer.
    Bachmann C; Schmidt S; Staebler A; Schittenhelm J; Wallwiener D; Grischke EM
    Med Oncol; 2014 Mar; 31(3):862. PubMed ID: 24504842
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Breast cancer with brain metastases: clinicopathologic features, survival, and paired biomarker analysis.
    Shen Q; Sahin AA; Hess KR; Suki D; Aldape KD; Sawaya R; Ibrahim NK
    Oncologist; 2015 May; 20(5):466-73. PubMed ID: 25802405
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is breast cancer from Sub Saharan Africa truly receptor poor? Prevalence of ER/PR/HER2 in breast cancer from Kenya.
    Sayed S; Moloo Z; Wasike R; Bird P; Oigara R; Govender D; Kibera J; Carrara H; Saleh M
    Breast; 2014 Oct; 23(5):591-6. PubMed ID: 25012047
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of the HER2, estrogen and progesterone receptor expression profile of primary tumor, metastases and circulating tumor cells in metastatic breast cancer patients.
    Aktas B; Kasimir-Bauer S; Müller V; Janni W; Fehm T; Wallwiener D; Pantel K; Tewes M;
    BMC Cancer; 2016 Jul; 16():522. PubMed ID: 27456970
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Breast cancer subtype as a predictor for outcomes and control in the setting of brain metastases treated with stereotactic radiosurgery.
    Grubb CS; Jani A; Wu CC; Saad S; Qureshi YH; Nanda T; Yaeh A; Rozenblat T; Sisti MB; Bruce JN; McKhann GM; Sheth SA; Lesser J; Cheng SK; Isaacson SR; Lassman AB; Connolly EP; Wang TJ
    J Neurooncol; 2016 Mar; 127(1):103-10. PubMed ID: 26615564
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Receptor conversion in distant breast cancer metastases.
    Hoefnagel LD; van de Vijver MJ; van Slooten HJ; Wesseling P; Wesseling J; Westenend PJ; Bart J; Seldenrijk CA; Nagtegaal ID; Oudejans J; van der Valk P; van der Groep P; de Vries EG; van der Wall E; van Diest PJ
    Breast Cancer Res; 2010; 12(5):R75. PubMed ID: 20863372
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discrepancies between biomarkers of primary breast cancer and subsequent brain metastases: an international multicenter study.
    Kaidar-Person O; Meattini I; Jain P; Bult P; Simone N; Kindts I; Steffens R; Weltens C; Navarria P; Belkacemi Y; Lopez-Guerra J; Livi L; Baumert BG; Vieites B; Limon D; Kurman N; Ko K; Yu JB; Chiang V; Poortmans P; Zagar T
    Breast Cancer Res Treat; 2018 Jan; 167(2):479-483. PubMed ID: 28975433
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discordances in ER, PR and HER2 receptors between primary and recurrent/metastatic lesions and their impact on survival in breast cancer patients.
    Yang YF; Liao YY; Yang M; Peng NF; Xie SR; Xie YF
    Med Oncol; 2014 Oct; 31(10):214. PubMed ID: 25216864
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 status in invasive breast cancer: a 3,198 cases study at National Cancer Center, China.
    Zhu X; Ying J; Wang F; Wang J; Yang H
    Breast Cancer Res Treat; 2014 Oct; 147(3):551-5. PubMed ID: 25234844
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Poor prognosis of single hormone receptor- positive breast cancer: similar outcome as triple-negative breast cancer.
    Bae SY; Kim S; Lee JH; Lee HC; Lee SK; Kil WH; Kim SW; Lee JE; Nam SJ
    BMC Cancer; 2015 Mar; 15():138. PubMed ID: 25880075
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Case to Case Comparison of Hormone Receptors and HER2 Status between Primary Breast Cancer and Synchronous Axillary Lymph Node Metastasis.
    Sujarittanakarn S; Himakhun W; Worasawate W; Prasert W
    Asian Pac J Cancer Prev; 2020 Jun; 21(6):1559-1565. PubMed ID: 32592349
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discordant expression of hormone receptors and HER2 in breast cancer. A retrospective comparison of primary tumors with paired metachronous recurrences or metastases.
    Arapantoni-Dadioti P; Valavanis C; Gavressea T; Tzaida O; Trihia H; Lekka I
    J BUON; 2012; 17(2):277-83. PubMed ID: 22740206
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Breast Cancer Survival Analysis Based on Immunohistochemistry Subtypes (ER/PR/HER2): a Retrospective Cohort Study.
    Poorolajal J; Nafissi N; Akbari ME; Mahjub H; Esmailnasab N; Babaee E
    Arch Iran Med; 2016 Oct; 19(10):680-686. PubMed ID: 27743431
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization.
    Basu S; Chen W; Tchou J; Mavi A; Cermik T; Czerniecki B; Schnall M; Alavi A
    Cancer; 2008 Mar; 112(5):995-1000. PubMed ID: 18098228
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characteristics of patients with brain metastases receiving trastuzumab for HER2 overexpressing metastatic breast cancer.
    Stemmler HJ; Kahlert S; Siekiera W; Untch M; Heinrich B; Heinemann V
    Breast; 2006 Apr; 15(2):219-25. PubMed ID: 16026983
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic values of negative estrogen or progesterone receptor expression in patients with luminal B HER2-negative breast cancer.
    Park C; Park K; Kim J; Sin Y; Park I; Cho H; Yang K; Bae BN; Kim KW; Ahn S; Gwak G
    World J Surg Oncol; 2016 Sep; 14(1):244. PubMed ID: 27619909
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Estrogen receptor (ER), progesterone receptor (PR), and HER2 expression pre- and post- neoadjuvant chemotherapy in primary breast carcinoma: a single institutional experience.
    Kinsella MD; Nassar A; Siddiqui MT; Cohen C
    Int J Clin Exp Pathol; 2012; 5(6):530-6. PubMed ID: 22949935
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pattern of hormone receptors and human epidermal growth factor receptor 2 status in sub-Saharan breast cancer cases: Private practice experience.
    Nwafor CC; Keshinro SO
    Niger J Clin Pract; 2015; 18(4):553-8. PubMed ID: 25966732
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.